|
Interferon beta-1a
drug data and news
Interferon beta-1a drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Interferon beta-1a
|
| Brand Names/Synonyms |
Interferon beta precursor;IFN-beta;Fibroblast interferon; Avonex (Biogen Inc) |
| Indication |
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum |
|
Sponsored links
|
|
Description |
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence of Avonex is identical to that of natural human interferon beta. |
| Pharmacology |
Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin and neopterin. |
| Mechanism Of Action |
Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha. |
Interferon beta-1a News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
LIQUID |
| Drug_Category |
Antiviral Agents; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00) |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Not Available |
| Chemical IUPAC Name |
Human interferon beta |
| Chemical Formula |
C908H1408N246O252S7 |
| Molecular Weight |
20027 |
| Smiles String |
Not Available |
| Melting Point |
Not Available |
| Water Solubility |
Not Available |
| State |
Transparent, slightly viscous, aqueous liquid |
| LogP/Hphobicity |
-0.427 |
| Isoelectric Point |
8.93 |
| Biotransformation |
Not Available |
| Half Life |
10 hrs |
| Protein Binding [%] |
Not Available |
| RxList Link |
RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.rxlist.com/cgi/generic3/rebif.htm |
| Drug Type |
Approved Drug |
| Accession No |
BIOD00093 |
| CAS Registry Number |
145258-61-3 |
| KEGG Compound ID |
Not Available |
| PubChem ID |
Not Available |
| PharmGKB ID |
PA10351 |
| SwissProt ID |
IFNB_HUMAN (P01574) |
| GenBank ID |
V00534 |
| Drug ID Number [DIN] |
2237319
|
|
|
